Jasper Therapeutics Stock Current Liabilities
| JSPR Stock | USD 20.47 1.84 8.25% |
Jasper Therapeutics fundamentals help investors to digest information that contributes to Jasper Therapeutics' financial success or failures. It also enables traders to predict the movement of Jasper Stock. The fundamental analysis module provides a way to measure Jasper Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jasper Therapeutics stock.
As of 12/12/2024, Total Current Liabilities is likely to drop to about 7.4 M. In addition to that, Non Current Liabilities Total is likely to drop to about 3.9 M. Jasper | Current Liabilities |
Jasper Therapeutics Company Current Liabilities Analysis
Jasper Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Jasper Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Jasper Therapeutics is extremely important. It helps to project a fair market value of Jasper Stock properly, considering its historical fundamentals such as Current Liabilities. Since Jasper Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jasper Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jasper Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Jasper Current Liabilities Historical Pattern
Today, most investors in Jasper Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Jasper Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Jasper Therapeutics current liabilities as a starting point in their analysis.
Jasper Therapeutics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Jasper Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Jasper Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Jasper Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jasper Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics of similar companies.Jasper Therapeutics is currently under evaluation in current liabilities category among its peers.
Jasper Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jasper Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jasper Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Jasper Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 246.65 M | ||||
| Shares Outstanding | 15 M | ||||
| Shares Owned By Insiders | 4.98 % | ||||
| Shares Owned By Institutions | 95.02 % | ||||
| Number Of Shares Shorted | 2.06 M | ||||
| Price To Book | 4.03 X | ||||
| EBITDA | (64.98 M) | ||||
| Net Income | (64.47 M) | ||||
| Cash And Equivalents | 60.81 M | ||||
| Cash Per Share | 1.60 X | ||||
| Total Debt | 2.79 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.56 X | ||||
| Book Value Per Share | 5.58 X | ||||
| Cash Flow From Operations | (52.07 M) | ||||
| Short Ratio | 9.32 X | ||||
| Earnings Per Share | (4.75) X | ||||
| Target Price | 68.78 | ||||
| Number Of Employees | 45 | ||||
| Beta | 2.2 | ||||
| Market Capitalization | 337.08 M | ||||
| Total Asset | 94.89 M | ||||
| Retained Earnings | (169.6 M) | ||||
| Working Capital | 76.56 M | ||||
| Net Asset | 94.89 M |
About Jasper Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jasper Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Jasper Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Jasper Stock
| 0.72 | IMAB | I Mab | PairCorr |
| 0.51 | GNFT | Genfit | PairCorr |
| 0.47 | LLY | Eli Lilly | PairCorr |
| 0.47 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.4 | FLGC | Flora Growth Corp Buyout Trend | PairCorr |
The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.
The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.